Insmed Inc (INSM)vsARS Pharmaceuticals, Inc (SPRY)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
SPRY
ARS Pharmaceuticals, Inc
$7.54
-1.69%
HEALTHCARE · Cap: $761.61M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 620% more annual revenue ($606.42M vs $84.28M). SPRY leads profitability with a -2.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
SPRY
Avoid18
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Conservative balance sheet, low leverage
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -92.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : SPRY
The strongest argument for SPRY centers on Debt/Equity.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : SPRY
The primary concerns for SPRY are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
SPRY generates stronger free cash flow (-43M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
INSM scores higher overall (39/100 vs 18/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
ARS Pharmaceuticals, Inc
HEALTHCARE · BIOTECHNOLOGY · USA
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine aerosol with absorption technology for patients and their families at risk of severe allergic reactions to food, medication, and insect stings. The company is headquartered in San Diego, California.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?